Where does afatinib (Giotrif) fit within the NSCLC treatment paradigm in Australia?

Lung cancer remains the leading cause of cancer death in Australia and the fourth most commonly diagnosed cancer.1 In May 2018, afatinib (Giotrif) became available on the PBS as monotherapy for the treatment of patients with advanced or metastatic non-squamous EGFR-mutation positive non-small cell lung cancer (NSCLC).2,3 To better understand where this therapy fits within the ...